VALNEVA SE ADR

NASDAQ: VALN (Valneva SE)

Kemas kini terakhir: semalam, 4:17PM

6.18

-0.15 (-2.37%)

Penutupan Terdahulu 6.33
Buka 6.23
Jumlah Dagangan 5,213
Purata Dagangan (3B) 80,096
Modal Pasaran 536,325,696
Harga / Jualan (P/S) 2.67
Harga / Buku (P/B) 2.87
Julat 52 Minggu
3.62 (-41%) — 9.50 (53%)
Tarikh Pendapatan 12 Aug 2025
Margin Keuntungan -7.22%
Margin Operasi (TTM) -38.61%
EPS Cair (TTM) -0.180
Pertumbuhan Hasil Suku Tahunan (YOY) 26.40%
Jumlah Hutang/Ekuiti (D/E MRQ) 119.34%
Nisbah Semasa (MRQ) 2.61
Aliran Tunai Operasi (OCF TTM) -67.22 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -83.02 M
Pulangan Atas Aset (ROA TTM) -10.03%
Pulangan Atas Ekuiti (ROE TTM) -7.91%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menurun Menurun
Biotechnology (Global) Menurun Menurun
Stok Valneva SE Menurun Menurun

AISkor Stockmoo

0.1
Konsensus Penganalisis 3.0
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata 0.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
VALN 536 M - - 2.87
RVMD 7 B - - 3.56
VRNA 6 B - - 27.21
CRNX 3 B - - 2.12
VRDN 1 B - - 2.44
ZYME 866 M - - 2.67

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Institusi 0.87%

Pemilikan

Nama Tarikh Syer Dipegang
General American Investors Co Inc 31 Dec 2024 354,361
Ironwood Investment Management Llc 31 Dec 2024 25,022
Vsm Wealth Advisory, Llc 31 Dec 2024 1,000
33.6533.6528.7028.7023.7523.7518.8018.8013.8513.85Harga Sasaran MedianQ3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
3.62 (-41%) — 9.50 (53%)
Julat Harga Sasaran
14.00 (126%) — 17.00 (175%)
Tinggi 17.00 (HC Wainwright & Co., 175.08%) Beli
Median 15.50 (150.81%)
Rendah 14.00 (Guggenheim, 126.54%) Beli
Purata 15.50 (150.81%)
Jumlah 2 Beli
Harga Purata @ Panggilan 6.72
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Guggenheim 08 May 2025 14.00 (126.54%) Beli 6.38
24 Mar 2025 15.00 (142.72%) Beli 7.43
HC Wainwright & Co. 15 Apr 2025 17.00 (175.08%) Beli 7.05
09 Apr 2025 17.00 (175.08%) Beli 6.77

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
12 May 2025 Pengumuman Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
12 May 2025 Pengumuman Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
07 May 2025 Pengumuman Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
07 May 2025 Pengumuman Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
07 May 2025 Pengumuman VALNEVA Declaration of shares and voting rights: April 30, 2025
07 May 2025 Pengumuman Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
07 May 2025 Pengumuman Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
26 Apr 2025 Pengumuman Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
26 Apr 2025 Pengumuman Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
18 Apr 2025 Pengumuman Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
18 Apr 2025 Pengumuman Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
16 Apr 2025 Pengumuman Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®
16 Apr 2025 Pengumuman Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®
14 Apr 2025 Pengumuman Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
14 Apr 2025 Pengumuman Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
09 Apr 2025 Pengumuman Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
09 Apr 2025 Pengumuman Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
03 Apr 2025 Pengumuman Valneva SE Shareholding Declaration - March 2025
01 Apr 2025 Pengumuman Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
01 Apr 2025 Pengumuman Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
31 Mar 2025 Pengumuman Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
31 Mar 2025 Pengumuman Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
26 Mar 2025 Pengumuman Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program
26 Mar 2025 Pengumuman Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program
25 Mar 2025 Pengumuman Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
25 Mar 2025 Pengumuman Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
24 Mar 2025 Pengumuman Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
24 Mar 2025 Pengumuman Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
20 Mar 2025 Pengumuman Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
20 Mar 2025 Pengumuman Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
05 Mar 2025 Pengumuman VALNEVA Declaration of shares and voting rights: February 28, 2025
03 Mar 2025 Pengumuman Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
03 Mar 2025 Pengumuman Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
28 Feb 2025 Pengumuman Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
28 Feb 2025 Pengumuman Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
Papar semua
6.666.666.476.476.296.296.106.105.925.92May 14May 14May 15May 15May 16May 16May 19May 19May 20May 20May 21May 21May 22May 22May 23May 23

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0500.050-0.000-0.000-0.050-0.050-0.100-0.100-0.150-0.150MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda